Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- PAFSC’s Second Committee Recommends Approval for Chugai’s Breast Cancer Drug Perjeta, Others
April 26, 2013
- Japan-Version NIH: Cabinet HQ to Lay Out Comprehensive Strategy, Integrate R&D Budgets
April 25, 2013
- Bill to Amend PAL Will Be Submitted to Diet in May, as Instructed by PM Abe: Mr Akagawa of PFSB
April 25, 2013
- MHLW Picks Additional Clinical Research Core Hospitals
April 23, 2013
- MHLW May Refuse Applications for Generic Drug Listing from Companies that Fail to Maintain Stable Supplies
April 23, 2013
- Experts on Council for Science and Technology Policy Back Measures to Promote Development of Innovative New Drugs Aiming at Healthy, Long-lived Society
April 19, 2013
- Reorganization of Council for Science and Technology Policy Proposed by Industrial Competitiveness Council to Create Stronger Centralized Authority
April 19, 2013
- First Committee to Discuss Approval of New Gout Treatment Topiroxostat
April 18, 2013
- Committee Finds No Problem with Quality of 8 Generic Versions of Pfizer Japan’s Unasyn-S Kit
April 18, 2013
- “Japanese Version of CTEP” Proposed at 1st Meeting of Expert Council on Future Cancer Research
April 16, 2013
- Growing Concern Over Return to Brand Names for Generics with Advent of Generic Versions of Combination Drugs
April 16, 2013
- PAFSC’s Second Committee to Review Chugai’s Breast Cancer Drug Pertuzumab on April 25
April 15, 2013
- Supreme Court Rejects Damage Claims in Iressa Suits; Govt, AZ Win 8-Year Battle
April 15, 2013
- Generic Roadmap: CSIMC Bill Payer Rep Says New 60% Target Could “Decelerate” Shift
April 12, 2013
- Cost-Effective Assessment Should Be Reflected in Pricing, Not Used as Criterion for Approval: Healthcare Reps at CSIMC
April 12, 2013
- CSIMC OKs NHI Price Listing of JT’s Anti-HIV Drug Stribild on Emergency Basis
April 11, 2013
- New Flu Act to Take Effect on April 13
April 11, 2013
- Japan Launches Strategic Fund for Drug R&D in Developing World
April 10, 2013
- MHLW Issues Order for Improvement to 5 Generic Companies due to GMP Violations by South Korean Supplier
April 9, 2013
- MHLW Unveils Generic Roadmap, Aims for 60%-Share by FY2017
April 8, 2013
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…